Zelgen(SH:688266) 智通财经网·2025-12-31 08:34Core Viewpoint - Zai Lab has entered into a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig), retaining rights in Greater China while granting AbbVie exclusive rights outside this region [1] Group 1: Agreement Details - AbbVie will receive exclusive development and commercialization rights for ZG006 outside of Greater China, which includes mainland China, Hong Kong, and Macau [1] - Zai Lab will receive an upfront payment of $100 million, along with milestone payments based on clinical progress and additional payments related to the licensing option, totaling up to $60 million [1] - If AbbVie exercises the licensing option, Zai Lab is eligible for up to $1.075 billion in milestone payments and will receive tiered royalties ranging from high single digits to mid-teens on net sales of the product outside Greater China [1]